Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | CRHR1 | P34998 | 11/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030093 | 0.86 | CRHR1 (0.44) | ESR1CRHR1 | |
| SCHEMBL4030022 | 0.86 | ESR1 (0.75) | ESR1ESR2CRHR1 | |
| SCHEMBL4028933 | 0.85 | ESR1 (0.74) | ESR1ESR2 | |
| SCHEMBL4033293 | 0.84 | ESR1 (0.54) | ESR1CRHR1 | |
| SCHEMBL4026375 | 0.84 | ESR1 (0.60) | ESR1ESR2 | |
| SCHEMBL4032697 | 0.83 | ESR1 (0.43) | ESR1ESR2CRHR1 | |
| SCHEMBL4027391 | 0.81 | ESR1 (0.73) | ESR1ESR2CRHR1 | |
| SCHEMBL4031100 | 0.77 | ESR1 (0.43) | ESR1ESR2CRHR1 | |
| SCHEMBL4025771 | 0.77 | ESR1 (0.56) | ESR1ESR2 | |
| SCHEMBL4027158 | 0.76 | ESR1 (0.45) | ESR1ESR2CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| US-7241791-B2 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2007-07-10 | — | — | US | disclosed |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | ESR1 1028/4885ESR2 621/4885CRHR1 2217/4885 |
| US-20040167127-A1 | Substituted 4-(indazol-3-yl)phenols | INSR, MSR1, TNNI3 | ESR1 2487/4885ESR2 605/4885CRHR1 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.